A systems biology investigation of neurodegenerative dementia reveals a pivotal role of autophagy

Laura Caberlotto* and Thanh-Phuong Nguyen

Abstract

Background: Neurodegenerative dementia comprises chronic and progressive illnesses with major clinical features represented by progressive and permanent loss of cognitive and mental performance, including impairment of memory and brain functions. Many different forms of neurodegenerative dementia exist, but they are all characterized by death of specific subpopulation of neurons and accumulation of proteins in the brain. We incorporated data from OMIM and primary molecular targets of drugs in the different phases of the drug discovery process to try to reveal possible hidden mechanism in neurodegenerative dementia. In the present study, a systems biology approach was used to investigate the molecular connections among seemingly distinct complex diseases with the shared clinical symptoms of dementia that could suggest related disease mechanisms.

Results: Network analysis was applied to characterize an interaction network of disease proteins and drug targets, revealing a major role of metabolism and, predominantly, of autophagy process in dementia and, particularly, in tauopathies. Different phases of the autophagy molecular pathway appear to be implicated in the individual disease pathophysiology and specific drug targets associated to autophagy modulation could be considered for pharmacological intervention. In particular, in view of their centrality and of the direct association to autophagy proteins in the network, PP2A subunits could be suggested as a suitable molecular target for the development of novel drugs.

Conclusion: The present systems biology investigation identifies the autophagy pathway as a central dis-regulated process in neurodegenerative dementia with a prevalent involvement in diseases characterized by tau inclusion and indicates the disease-specific molecules in the pathway that could be considered for therapy.

Keywords: GSK-3β, AMPK, Frontotemporal dementia, Alzheimer’s disease, Lewy bodies disease, Progressive supranuclear palsy, Corticobasal dementia, Pick’s disease, Amyotrophic lateral sclerosis-Parkinsonism/dementia complex

Background

Dementia is a clinical syndrome that characterizes many different etiologies, including neurodegenerative, metabolic, vascular, and infectious diseases defined by a cluster of symptoms and signs manifested by difficulties in memory, disturbances in language, psychological and psychiatric alterations, and impairments in daily living activities. The neurodegenerative dementias can be caused by a multiplicity of conditions or diseases that lead to the progressive and irreversible degeneration of specific populations of neurons and their connections. The most common cause of neurodegenerative dementia is Alzheimer’s disease, less frequent causes include, among other, Lewy body dementia, frontotemporal dementia, and Prion disease.

Individual neurodegenerative dementia diseases are characterized histologically by varying grades of neuronal loss, gliosis, and abnormal accumulation of proteins. The nature of protein deposition defines the histological classification of each neurodegenerative dementia in two major groups: tauopathies and synucleinopathies, associated with the pathological aggregation of tau or alpha-synuclein...
proteins in the brain, respectively [1,2]. Despite increasing global prevalence, the precise neurobiological basis and terms for objective diagnosis of neurodegenerative dementias remain controversial, and comprehensive understanding of the neurobiology basis of the diseases remains lacking. Moreover, heterogeneous clinical presentations of the same molecular pathology, comorbidity or unexpected pathologies which characterize the aging brain and a strong clinical and pathological overlap between distinct neuropathological diagnoses render insights in the different disorders extremely important for diagnostic purposes.

The molecular background of the phenotypic variability in neurodegenerative dementia has been investigated and a spectrum of relations between clinical syndromes and molecular features has been identified. Although some proteins have emerged as important players in the mechanism of neurodegeneration, the precise molecular machinery involved in neurodegeneration remains largely unknown.

Systems biology has been paving the way to the exploration of complex associations of diseases and, thus, to the inference of the pathogenic mechanism of a particular disease by considering disease-related components in a large-scale network [3-5]. Although systems biology approach could be limited by its deterministic view of genes as influencing various phenotypes, and by the lack of appreciation of physiological regulation and of cultural and environmental aspects, it could, however, give advantages over the narrow view of what constitutes ‘traditional biology’. Molecular networks, particularly protein-protein interaction networks (PIN), are extraordinarily informative because it is well-known that most cellular components do not solely perform the biological functionality, but interplay with other cellular components in an intricate interaction network [4-8]. Human PIN has been a valuable data resource to study molecular pathogenesis for a wide range of diseases [6-13]. Among those, numerous studies have been carried out to deeply understand the molecular networks related to neurodegenerative diseases (NDs), proposing different methodological approaches including network analysis to study Alzheimer’s disease based on PIN and data integration [14], inference of overlapping regulators of NDs in different organisms [15], pathway-based method to uncover the direct commonality among NDs [16], or reconstruction of NDs network based on PPI networks, regulatory networks, and Boolean networks [17]. In addition to disease genes study, systems biology approach has been also applied to drug target elucidation [18]. Yu et al. proposed a systematic approach that used of Random Forest and Support Vector Machine for predicting drug targets by combining the chemical, genomic, and pharmacological information [19]. In Emig et al. [20], a disease gene expression signature and a high-quality interaction network were integrated using network-based approach to prioritize the list of drug targets. Thus, systems biology application in pharmacology hold promises for drug discovery.

The aim of the present study was to identify key molecular hubs relevant for neurodegenerative dementia using a network-based approach in a context of protein-protein interaction. The diseases studied were: Frontotemporal dementia (FTD), Alzheimer disease (AD), Lewy bodies disease (LBD), Progressive supranuclear palsy (PSP), Corticobasal dementia (CBD), Pick’s disease, Prion disease, Hungtington’s disease and Amyotrophic lateral sclerosis-Parkinsonism/ dementia complex. Both Tauopathies and synucleinopathies were included to try to uncover any molecular alteration characterizing these subgroups of dementia-related diseases. This is the first attempt of application of systems biology methodology to reveal the molecular complexity of this subgroup of neurodegenerative disorders integrating not only the current knowledge on the specific diseases (OMIM), but also the drug targets, representing the broadest coverage of the genes that has been considered relevant for the treatment of dementia-associated symptoms. This integration of network analysis in biomedical research has uncovered hidden molecular pathways that are mutual between distinct diseases sharing the common symptoms of dementia and provided further support to the hypothesis of alteration in autophagy as the molecular basis of these groups of neurodegenerative disorders, particularly tauopathies.

Methods
The study pipeline is presented in Figure 1 and it is composed by three major steps: (1) Reconstruction of the interaction network by integrating OMIM disease genes, drug target genes and PIN, (2) Analysis of the interaction network of disease genes and drug targets, and (3) Functional annotations analysis of disease genes and drug targets. The three steps are described in details in the following subsections.

Reconstructing integrating networks of disease genes and drug targets
Three datasets were used to construct the network: OMIM disease genes, drug target genes and protein interaction network.

OMIM disease seed genes
Disease genes and genetic phenotypes of the different neurodegenerative dementia diseases (Table 1) were extracted from the OMIM database [21], a comprehensive, authoritative compendium of human genes and genetic phenotypes [22]. Keywords that are most relevant for the disorders were defined, such as the official disease names and alternative names. A text mining process was
performed to extract genes related to the dementia keywords in the OMIM database.

**Drug target seed genes**

Drug molecular targets were obtained by collecting information from different pharmaceutical company websites, from a clinical trial database (www.clinicaltrial.gov) and from the Drug Bank (www.drugbank.ca) (Additional file 1: Table S1). Drugs for the treatment of dementia in all phases of the drug discovery process, from preclinical to marketed drugs, were included. This approach allowed obtaining the broadest coverage of the genes of interest for pharmaceutical drug development to identify the overall key molecular targets of interest for the treatment of dementia. Only primary targets were considered as seed genes for network analysis.

**Protein-protein interaction network**

The protein interaction network integrating dementia genes and drug target was extracted from the Interologous Interaction Database (i2d) [23], which is an integrated database of the majority of all known experimental and predicted human protein interaction data sets (including HRPD, BIND, BioGrid, etc.). The database consisted of 846,116 interactions in total, with 173,338 homo sapiens-related. To construct a PIN related to dementia, we firstly extracted the corresponding product proteins of the seed genes (diseases and drug target). We used the ID mapping scheme provided by the Uniprot database to map the seed gene symbols to the Uniprot protein accessions. Consequently, two sets of proteins were obtained, the set of disease proteins $S_{DG}$ corresponding to the OMIM disease seed genes, and the set of drug target proteins $S_{DT}$ corresponding to drug target seed genes. Based on these two sets $S_{DG}$ and $S_{DT}$, we then extracted PIN by processing raw data of protein-protein interactions (PPI) in the i2d database. All the homologous predicted protein interactions in the i2d database were excluded to increase the reliability of the protein interaction data. The final interaction network contained the nodes representing disease proteins and drug targets, and the edges representing their protein interactions (Figure 2). We took into account only direct interactions (i.e., one-step neighbors). The network was undirected and unweighted because we considered the binary interactions.

**Network analysis**

To gain information on the network and their participating proteins, we evaluated the centrality of proteins in the network. In view of the fact that the functional importance of proteins might be inferred from their central roles in the network [24-26], we computed the degree index for each protein, one of the most applied indices to evaluate the centrality in the network.

A graph $G(V,E)$ consists of a set of vertices $V$ and a set of edges $E$ between them. An edge $e_{ij}$ connects...
vertex $v_i$ with vertex $v_j$. Here, an undirected graph is investigated since our studied protein interaction networks are undirected. An undirected graph has the property that $e_{ij}$ and $e_{ji}$ are considered identical. Therefore, the neighbourhood $N_i$ for a vertex $v_i$ is defined as its direct connected neighbours by Equation (1):

$$N_i = \{ v_j : e_{ij} \in E \}$$

(1)

The degree $D_i$ of a vertex is defined as the number of vertices $|N_i|$, in its neighbourhood $N_i$.

We then computed different network measures to comprehend the topological properties of the constructed network (Table 2).

- **Number of connected components**: A connected component is a group of all nodes that are pairwise connected. The number of connected components indicates the connectivity of a network — a lower number of connected components suggest a stronger connectivity.

- **Measures to shortest paths**: The length of a path is the number of edges forming it. There may be multiple paths connecting two given nodes. The shortest path length, also called distance, between two nodes $n$ and $m$ is denoted by $L(n, m)$.

- **Network diameter**: the largest distance between two nodes. If a network is disconnected, its diameter is the maximum of all diameters of its connected components.

- **Network radius**: the smallest distance between two nodes.

- **Average shortest path length**: also known as the characteristic path length, gives the expected distance between two connected nodes.

- **Average number of neighbors**: indicates the average connectivity of a node in the network.

- **Network density**: a normalized value of the average number of neighbors.

- **Network centralization**: a simple and widely used index of the connectivity distribution. Networks whose topologies resemble a star have a centralization close to 1, whereas decentralized networks are characterized by having a centralization close to 0.

- **Network heterogeneity**: reflects the tendency of a network to contain hub nodes.

- **Clustering coefficients**: In undirected networks, the clustering coefficient $C_{n}$ of a node $n$ is defined as $C_{n} = 2e_{n}/(k_{n}(k_{n}-1))$, where $k_{n}$ is the number of neighbors of $n$ and $e_{n}$ is the number of connected pairs between all neighbors of $n$. The clustering coefficient is a ratio $N / M$, where $N$ is the number of edges between the neighbors of $n$, and $M$ is the maximum number of edges that could possibly exist between the neighbors of $n$. The network clustering coefficient is the average of the clustering coefficients for all nodes in the network.

### Table 1 Neurodegenerative dementia diseases with their relative disease proteins and protein marker

| Disease | Disease protein | Official gene symbol | Protein marker |
|---------|----------------|---------------------|---------------|
| Alzheimer | P05067 | APP | Tau |
| Alzheimer | P01023 | A2M | Tau |
| Alzheimer | P49768 | PSEN1 | Tau |
| Alzheimer | Q6ZV49 | PAXIP1 | Tau |
| Alzheimer | P49810 | PSEN2 | Tau |
| Alzheimer | P29474 | NOS3 | Tau |
| Alzheimer | P05164 | MPO | Tau |
| Alzheimer | Q92870 | APBB2 | Tau |
| Alzheimer | P02649 | APOE | Tau |
| Alzheimer | P00749 | PLAU | Tau |
| Alzheimer | Q30201 | HFE | Tau |
| Alzheimer | Q92673 | SORL1 | Tau |
| Alzheimer | P12821 | ACE | Tau |
| Alzheimer | Q13867 | BLMH | Tau |
| Amyotrophic lateral sclerosis-Parkinsonism/ Dementia complex | Q99497 | PARK7 | Tau |

List of neurodegenerative dementia diseases, proteins (Uniprot ID) associated to the disease as obtained from OMIM database and related Official Gene Symbol and protein markers related to the diseases.
To investigate the proteins potentially related to dementias, we determined mediator proteins, which are defined as proteins that have direct interactions with both proteins in the set of $S_{DG}$ and of $S_{DT}$. First, based on the PIN extracted, we searched the direct neighbours $v_j$ of all proteins $v_i$ where $v_j \in S_{DG}$ denoted $I_{DG} = \{v_j\}$. Similarly, we obtained the set $I_{DT} = \{v_k\}$, where $v_k$ is direct neighbours of proteins $v_i$ and $v_i \in S_{DT}$. Then the set of mediator proteins is the intersection set of the two sets $I_{DG}$ and $I_{DT}$, denoted $M$ by Equation (2).

$$M = I_{DG} \cap I_{DT}$$ (2)

List of mediator proteins is shown in Additional file 1: Table S1.

**Functional annotation analysis**

The complete lists of mediator proteins and the sub-list related to tauopathies (Table 1) were used to extract the most representative GO biological process terms (i.e., the ones that are over-represented, but that do not refer to most general biological processes). For identifying and visualizing enriched GO terms, we used GOrilla and REVIGO tools [27,28]. Hypergeometric distribution was applied to test GO term enrichment, and a p-value threshold of 0.001 was selected. The output graphs were obtained from REVIGO, a web server that considers long lists of Gene Ontology terms and summarizes them by removing redundant GO terms. These terms can be visualized in semantic similarity-based scatterplots and this graph-based visualization accurately renders the subdivisions and the semantic relationships in the data. Each of the GO terms is a node in the graph, and 3% of the strongest GO term pairwise similarities are designated as edges in the graph (Figures 3, 4, and Additional file 2: Figure S2).

In depth analysis of specific GO terms-associated genes was performed. In particular, among the metabolic-related GO terms indicated by the functional enrichment analysis of the complete list of mediators and of the tauopathies-associated sub-list (Figures 3 and 4), autophagy was selected for further analysis. Thus, the proteins list related to GO terms associated to autophagy (GO:0006914 and...
GO:0006914; Additional file 1: Table S1) were studied and, in addition, for a complete coverage of the autophagy associated genes in the mediator list, other mediator proteins that have been demonstrated to be involved in autophagy process as described in Uniprot (keyword: autophagy) were included in the analysis. In addition to the GO-enrichment analysis, we explored the human autophagy network [29] to investigate the centrality of our mediators in the context of an experimentally validated human autophagy network [29]. Behrends et al. used a modified version of the Comparative Proteomics Analysis Software Suite to identify the autophagy interaction network (AIN) of 409 non-redundant high-confidence candidate interaction proteins (HCIPs), making 751 interactions. They then employed hierarchical clustering in AIN to model ten functional sub-networks. We carried out two different analyses, first on the complete AIN and, second, on the functional clustered network. Firstly we computed the intersection of the mediator list obtained by our method and the list of interacting proteins in the complete AIN, to study the coverage and the topological roles of the mediators. The degree centrality and articulation position were calculated for all mediators based on the AIN. A node is considered an articulation point (or cut vertex) if, and only if, by removing it (and edges through it) we disconnect the graph. Subsequently, to discover the functional roles of mediators related to autophagy, we compared the mediator list with the list of 32 primary baits and 33 secondary baits in the functional sub-networks described in Behrends et al. paper [29].

**Results**

We obtained the integrated network consisting of 3,450 proteins and 7,367 interactions. Table 2 shows the statistics of the integrated network. There are 6 connected components and, among them, there exists a giant component (the largest connected components) consisting of 3,435 proteins (99.57% of the total number of proteins) and 7,251 interactions (98.43% of the total number of interactions). Thus, the network is well-connected and comprehensive for network analysis. The shortest path length and neighborhood measures showed that the network is centralized in a number of hubs, and proteins in the network are close to each other and easily reached through short paths. Using the degree index, highly-ranked proteins were extracted as shown in Table 3. The functional annotation analysis of the highly ranked proteins revealed a predominant role of metabolic processes including regulation of energy homeostasis, glucose and lipid metabolism (Additional file 2: Figure S2 and Additional file 1: Table S1). The proteins associated to these metabolic-related GO terms are mainly AMPK subunits (PRKAA1 and PRKAA2) and NF-kB. Cell receptor signaling pathways with terms associate to TRK

**Figure 3** Summary of statistically significant Gene Ontology biological processes functional annotation corresponding to proteins in the mediator list as obtained from REVIGO [28]. Nodes are GO terms and edges represent the strongest GO terms pairwise similarity. Colors represent the p-values (low values in green, high in red). Only significant GO terms are shown (P < 0.001).
receptor and Wnt receptor pathways were also significantly enriched (Additional file 1: Table S1).

Functional enrichment analyses of GO biological process terms were also performed for the complete list of mediators, showing metabolic related terms, immune response and inflammatory processes, and cell surface receptor signaling pathways (Figure 3 and Additional file 1: Table S1). Considering mediator protein associated to Tauopathies, similar functional annotations were presented with the addition of terms related to cell death and cognition-related terms, such as synaptic transmission and learning and memory (Figure 4 and Additional file 1: Table S1). Based on the increasing interest of the role of metabolism in dementia, a major focus was dedicated to the metabolic processes associated terms, in particular to autophagy. As described in Table 4, 27 mediators are involved in autophagy processes or in the regulation of autophagy.

The disease genes associated to the autophagy mediators are shown in Figure 5 and listed in Table 4, while in Figure 6, the drug targets directly associated to the autophagy mediators are represented. A prevalence of subunits of Protein Phosphatase 2A (PP2A), was evident and highlighted in the figure.

By investigating the overlaps between the mediator list obtained and the human autophagy network as described in Behrends et al. paper [29], 45 mediators were found in the network (Additional file 3: Table S3). Eight mediators were found in top 10 central nodes in the network by ranking the degree centrality. Moreover, 24/45 mediators were the articulation nodes that are of high interest as the important nodes to prevent network fragmentation (Additional file 3: Table S3). The centrality and crucial positions in the autophagy interaction network of the mediators highlighted their relevant role in the autophagy process (Figure 7A). By analyzing the 10 functional
network clustered in the AIN, we found 25 mediator proteins in the network. The autophagy-related mediator proteins were not predominantly belonging to any of the sub-networks described by Behrends and collaborators, but they are present in almost all sub-networks (Figure 7B). FTD-associated mediator proteins (Table 4) were found in protein kinase network, vesicle elongation and autophagosome assembly and vesicle nucleation autophagy phases, while AD-associated proteins were seen only in the protein kinase network, vesicle elongation and autophagosome assembly stages (Figure 7C).

Discussion
In the present study, network analysis was used to explore from the systems biology perspective, the molecular connections among multifactorial complex diseases with the shared clinical symptoms of dementia, which could suggest related disease mechanisms. A number of diseases were considered, both common (e.g. Alzheimer’s disease) and rare disorders (e.g. amyotrophic lateral sclerosis with parkinsonism and dementia) that have as a common and major symptom a progressive and permanent loss of cognitive and mental performance (Table 1).

While previous systems biology studies on disease focus on the disease gene network or drug target network, separately, the method proposed in the current study presented an integrated methodology that can take advantage of both these data, providing further insight into the interactome related to dementia.

Among the most connected proteins (with more than 100 interactions in the network; Table 3) the first 2 proteins in the list were PRKAA1 and PRKAA2, subunits of AMPK. AMPK is a central regulator of energy homeostasis controlling neuronal maintenance in response to metabolic stress. Latest research support an involvement of AMPK in Alzheimer [30,31] and, in our previous study on Alzheimer’s disease, on a separate set of data and with a very different systems biology methodological approach, AMPK-related genes were also found to be strongly associated to the disease [14]. Moreover, abnormal neuronal accumulation of activated AMPK (pAMPK) has been described in different tauopathies including PSP, AD, Pick’s disease, and CBD [32]. Thus, the present findings support once more the proposed hypothesis of an alteration of metabolic functions and energy regulation in dementia.

Considering the complete list of mediator proteins, Gene ontology (GO) enrichment analysis confirmed a significant involvement of metabolic signaling regulating energy homeostasis, lipid and glucose metabolism (Figure 3). Metabolic disturbances have been strongly associated to or considered a predisposing factor in AD and a metabolic/signal transduction hypothesis for AD and other tauopathies has been suggested by Iqbal et al. [33]. Amongst

| Uniprot ID | Official gene symbol | Gene name | Degree index |
|------------|----------------------|-----------|--------------|
| Q13131     | PRKAA1               | Protein kinase, AMP-activated, alpha 1 catalytic subunit | 419          |
| P54646     | PRKAA2               | Protein kinase, AMP-activated, alpha 2 catalytic subunit | 392          |
| P03372     | ESR1                 | Estrogen receptor | 250          |
| P19838     | NFKB1                | Nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 | 247          |
| Q13547     | HDAC1                | Histone deacetylase 1 | 218          |
| Q00005     | PPP2R2B              | Protein phosphatase 2 (formerly 2A), regulatory subunit B, beta isoform | 201          |
| P17252     | PRKCA                | Protein kinase C, alpha | 194          |
| P49841     | GSK3B                | Glycogen synthase kinase 3 beta | 170          |
| P06493     | CDK11                | Cell division cycle 2, G1 to 5 and G2 to M | 163          |
| P04150     | NR3C1                | Nuclear receptor subfamily 3, group C, member 1 (glucocorticoid receptor) | 156          |
| Q92769     | HDAC2                | Histone deacetylase 2 | 138          |
| P05067     | APP                  | Amyloid beta (A4) precursor protein | 136          |
| P19438     | TNFRSF1A             | Tumor necrosis factor receptor superfamily, member 1A | 133          |
| P67775     | PPP2CA               | Protein phosphatase 2 (formerly 2A), catalytic subunit, alpha isoform | 127          |
| P20226     | TBP                  | TATA box binding protein | 126          |
| P24941     | Cdk2                 | Cyclin-dependent kinase 2 | 125          |
| P30153     | PPP2R1A              | Protein phosphatase 2 (formerly 2A), regulatory subunit A, alpha isoform | 121          |
| P54259     | ATN1                 | Atrophin 1 | 109          |
| P50750     | Cdk9                 | Cyclin-dependent kinase 9 | 102          |

In bold is the mediator which is also disease proteins, having direct interactions with drug targets and other disease genes.
the metabolic-related terms, a role for autophagy and regulation of autophagy was highlighted (Figures 3 and 4). Although autophagy has been known for decades, its relevance in neurons and glial physiology has been demonstrated only recently [34]. Autophagy is involved in the intracellular turnover of proteins and cell organelles.

### Table 4 Autophagy-related proteins and association with dementia disease proteins

| Disease | Disease protein | Disease protein | Mediator autophagy | Mediator autophagy |
|---------|----------------|----------------|--------------------|--------------------|
|         | Uniprot ID     | Official gene symbol | Uniprot ID | Official gene symbol |
| AD      | P02649         | APOE            | P10636            | MAPT               |
| AD      | P05067         | APP             | P00519            | MAPT               |
| AD      | P05067         | APP             | P49768            | PSEN1              |
| AD      | P05067         | APP             | P10636            | MAPT               |
| AD      | P05067         | APP             | P07339            | CTSD               |
| AD      | Q13867         | BLMH            | Q13131            | PRKAA1             |
| AD      | Q13867         | BLMH            | Q06XW4            | MAP1LC3C           |
| AD      | P29474         | NOS3            | P31749            | AKT1               |
| AD      | P49810         | PSEN2           | P49768            | PSEN1              |
| AD      | Q92673         | SORL1           | Q9HIYD            | ATG5               |
| AD      | Q92673         | SORL1           | Q90CD7            | AMBRA1             |
| AD      | Q92673         | SORL1           | Q13131            | PRKAA1             |
| FTD     | Q13148         | TARDBP          | Q62NE5            | ATG14/ KIAA0831    |
| FTD     | Q13148         | TARDBP          | Q95166            | GABARAP            |
| FTD     | Q13148         | TARDBP          | P54646            | PRKAA2             |
| FTD     | Q13148         | TARDBP          | Q13286            | CLN3               |
| FTD     | Q13148         | TARDBP          | Q5MNZ9            | WPI1               |
| FTD     | Q13148         | TARDBP          | Q676U5            | ATG16L1            |
| FTD     | Q13148         | TARDBP          | Q68384            | C12orf44/ ATG101   |
| FTD     | Q13148         | TARDBP          | Q9HIYD            | ATG5               |
| FTD     | Q13148         | TARDBP          | Q9Y484            | WDRA5              |
| FTD     | Q13148         | TARDBP          | Q9Y4P8            | WPI2               |
| FTD     | P49768         | PSEN1           | P10415            | BCL2               |
| FTD     | P49768         | PSEN1           | Q07817            | BCL2L1             |
| FTD/PSNP| P10636         | MAPT            | O60260            | PARK2              |
| FTD/PSNP| P10636         | MAPT            | P00519            | ABL1               |
| FTD/PSNP| P10636         | MAPT            | P31749            | AKT1               |
| FTD/PSNP| P10636         | MAPT            | P49768            | PSEN1              |
| FTD/PSNP| P10636         | MAPT            | Q13501            | SQSTM1             |
| ALSLPD  | Q99497         | PARK7           | Q06ZNE5           | ATG14/ KIAA0831    |
| ALSLPD  | Q99497         | PARK7           | Q9Y484            | WDRA5              |
| ALSLPD  | Q99497         | PARK7           | Q13286            | CLN3               |
| ALSLPD  | Q99497         | PARK7           | Q9HIYD            | ATG5               |
| ALSLPD  | Q99497         | PARK7           | Q9Y4P8            | WPI2               |
| ALSLPD  | Q99497         | PARK7           | Q15831            | STK11              |
| ALSLPD  | Q99497         | PARK7           | Q9P2YS            | UVRAG              |
| ALSLPD  | Q99497         | PARK7           | Q7Z6L1            | TECPR1             |
| LBD     | P37840         | SNCA            | Q9HIYR8           | GABARAPL1/3/ ATG8  |
| LBD     | P37840         | SNCA            | Q92934            | BAD                |

In bold are the mediators protein which are also disease proteins.
AMPK is one of its main regulators [37]. In neurons, it is involved in cellular homeostasis and cellular protein clearance pathway and for the remodeling of terminals in support of neuronal plasticity [38]. In glial cells, autophagy is implicated in the elimination not only of glial proteins, but also of those secreted by neurons, which otherwise would accumulate in the extra-neuronal space [39], and it is activated in astrocytes following injury [40]. Thus, it is not surprising that neurodegenerative dementia diseases, which have been linked to the abnormal accumulation of proteins and to alteration of synaptic plasticity, have been associated to the autophagic system [41]. Moreover, a potential role of autophagy in dementia is also suggested by the expression profile extracted from Mantra (http://mantra.tigem.it/), a transcriptional response database of FDA approved drugs, of 2 drugs clinically in use for the treatment of Alzheimer's disease: galantamine and memantine. Several genes are modulated including AMBRA1, GABARAPL1, CLN3, SQSTM1, and AMPK subunits. Detailed examination of autophagy-related genes in the mediator list, showed a preferential association to tauopathies, as demonstrated also by the GO enrichment study in the subset of mediators linked to dementia disease characterized by Tau protein inclusions (Figure 4). Autophagy process consists of several sequential steps including protein kinase network regulating the system, vesicle elongation, autophagosome assembly, and vesicle nucleation (Figure 7C) [29] and specific autophagy dysfunctions could explain the diverse pathological course of the disorders. Analyzing in more detail these autophagy mediators and the molecular link to the specific disease genes, AD and FTD-related mediator proteins appears to be mainly associated to the initiation complex of the
macroautophagy cascade, involving mainly beclin 1 interactome: B-cell CLL/lymphoma 2 (BCL2), BCL2-like 1 (BCL2L1), and Atg14 (Figure 6). Beclin 1 interactome contains stimulating and suppressive components regulating the initiation of the autophagosome formation and, recently, Beclin 1 has been found to be down-regulated in AD brain. Moreover, suppression of Beclin 1 in cultured neurons and transgenic mice induces the deposition of amyloid-β peptides, whereas its overexpression reduces its accumulation [42]. Beclin 1 protein also assembles two core complexes, Atg14L or UVRAG complexes, and with Atg14L protein induces the phagophore formation, whereas the UVRAG/Beclin 1 complex controls other Beclin 1-dependent functions, e.g. phagocytosis. The subcellular compartmentation of Beclin 1 is regulated by different molecules including BCL-2 [43] and mTOR [44] which are represented in the mediator list. Several proteins can control the activation of beclin complex including two protein kinases included in our mediator list: CKD2 and CDK5 [45] (Additional file 1: Table S1). Atg5 protein, a mediator related to both AD and FTD disease genes (Figures 5 and 6), is also essential for the autophagy process and, in a conjugated form with Atg12 and Atg8 (LC3), is involved in the early stages of autophagosome formation (Figure 7C). Taken together these results suggest impairment in the early stages of autophagy complex essential for autophagosome formation [46,47], including protein kinase network regulating autophagosome assembling. The hypothesis that autophagy regulation and, in particular, its induction could contribute to AD pathology is also supported by recent evidence suggesting that the synthesis of components of the lysosome is up-regulated at the transcriptional and translational levels in the AD brain.

Figure 6 Autophagy-associated drug target sub-network. In the network are shown the drug targets (yellow squares) and the associated autophagy-related mediator proteins (blue circles). In red are highlighted the PP2A proteins subunits.
and AD mouse models [48-54]. Moreover, Lipinski et al. [55] recently reported an up-regulation of the transcription of genes stimulating autophagy and a down-regulation of the negative regulators of autophagy in the brains of AD affected subjects. In the dementia network, this interactome is connected to presenilin (Figure 5) whose mutation underlies the majority of familial Alzheimer’s disease cases [56-58] and whose role in autophagy has been shown to be central [59], presenilin 1 being essential for lysosome acidification, and proteolysis during autophagy [60].

Frontotemporal dementia-related mediator proteins seem to be involved not only in the vesicle elongation and autophagosome assembling process, but also, and exclusively, to vesicle nucleation procedure (Figure 7C). This process includes WIPI proteins (WD-repeat protein interacting with phosphoinositides), WIPI-1 and WIPI-2, evolved from the yeast ancestral autophagy protein Atg18 (Proikas-Cezanne T, 2004; Polson HE, 2010) as membrane components of autophagosomes (Mauthe 2011, [61]). Both WIPI-1 and WIPI-2 specifically bind PtdIns(3)P and localize at autophagosomal membranes (phagophore) [62].

TARDPB (TDP-43) appears to be a central protein in our autophagy-related sub-network (Figure 5). TDP-43 is a DNA/RNA-binding protein with multicellular functions. Several mutations of its gene have been reported in cases of frontotemporal lobar degeneration (FTLD) [63]. It is processed and degraded by both autophagy and the ubiquitin-proteasome systems [64]. Activation of autophagy by rapamycin plays an active role in the clearance of TDP-43 deficits in mouse model with proteinopathies of the TAR DNA-binding protein 43 [65]. Depletion of TDP-43 induces a down-regulation of the major autophagy component Atg7, causes impairment of autophagy.

**Figure 7** Integration of neurodegenerative dementia mediator proteins with human autophagy network (modified from [29]). In A) mediator proteins of the dementia network are charted in the human autophagy interaction network, in B) mediator proteins are mapped in the human autophagy sub-networks and in C) mediator proteins are highlighted in the functional integration of the autophagy interaction network.
and facilitates the accumulation of polyubiquitinated proteins which could be rescued by overexpression of the protein, with a feedback regulatory loop between TDP-43 and autophagy [64]. In our network, TDP-43 is linked to AMPK subunit PRKAA2 and a functional link between these two proteins has been suggested in pathological conditions showing that activated AMPK adversely affects mutant TDP-43-induced motor neurons diseases [66]. In addition, it is related to other central autophagy proteins such as ATG5 and ATG16L, which create a multimeric complex playing an essential role in autophagosome formation, a system highly conserved in all eukaryotes [67]. The other proteins linked to TDP-43 are WIPI proteins and ATG5-ATG16 complex for the treatment of FTD and other diseases involving mutations in TDP-43 gene.

Apart from the metabolic-associated biological processes terms, cell surface receptor signaling pathways-related terms were also highly significant enriched, in particular in proteins associated to the Wnt pathway (Figures 3 and 4). Several proteins in the mediator list are represented in the pathway (see Additional file 4: Figure S4) including GSK-3β, a tau kinase that was also included in the most connected mediator proteins list (Table 3) and in the autophagy-related proteins (Additional file 3: Table S3). Several preclinical and clinical data strongly link GSK-3β to dementia: different inhibitors of GSK3β activity block neurodegeneration in vitro, and GSK-3β-mediated Wnt signaling can mediate amyloid peptide toxicity in vitro [68,69]. Finally, in human post-mortem brain, this protein is physically associated with neurofibrillary tangles, one of the pathologic hallmarks of AD [70]. WNT pathway has also been recently linked to autophagy. In fact, autophagy negatively regulates Wnt signalling by promoting Dishevelled (Dvl) degradation, with a role for Von Hippel–Lindau protein-mediated ubiquitylation [71], both of them present in the dementia network mediator list.

In our dementia network, among the drug targets associated to the autophagy-related mediators, the highest represented proteins are subunits of the Protein phosphatase 2A (PP2A; Figure 5), a serine/threonine-specific protein phosphatase consisting of A, B and C subunits that plays multiple roles in different signaling pathways and regulates diverse cellular processes. Among the six PP2A proteins, three proteins (PPP2R2B, PPP2CA, and PPP2R1A) are also listed in the highly ranked proteins in the dementia network (Table 3), demonstrating their centrality. A recent study confirms that PP2A blockade inhibits autophagy potentially through activation of AMPK [72]. A role of PP2A in dementia is further demonstrated by the evidence that okadaic acid and calyculin A, two potent PP2A inhibitors [73], are able to induce tauopathy and cognitive deficiency in rats [74,75]. Thus, PP2A subunits could be considered as a potential therapeutic target for AD.

In our drug targets list related to autophagy mediators (Figure 6), other molecular targets could be considered suitable for therapeutic intervention including AMPK-related proteins, a highly ranked protein in our network (Table 3 and Additional file 3: Table S3) and a target which has been already considered for the treatment of Alzheimer’s disease. In fact, pioglitazone, an antidiabetic drug which acts also by activating AMPK [76], has been proven to reverse pathological conditions in an animal model of the disease [77] and it is in clinical trial for Alzheimer’s disease (www.clinicaltrial.gov).

In more general terms, a direct action on the regulation of autophagy, potentially an activation of the autophagic process should be considered to the development of optimal therapeutics, although autophagy can function both as a cytoprotective mechanism, but it also has the capacity to cause cell death.

Conclusion

This network analysis considering the established knowledge on different neurodegenerative dementia disease represented by OMIM data and the drug targets in the different phases of the drug discovery process, identifies the autophagy process as a central dis-regulated pathway in these sub-group of neurodegenerative disorders. We could hypothesize that different mutation or alteration at the genomic level could affect different phases of the autophagy process and thus therapeutic modulation could involve approaches that functionally target the specific proteins. Exploring the molecular mechanisms of autophagy opens an avenue for development of novel drugs and particularly, these results could suggest the potentiality of drug targeting specific PP2A subunits for the treatment of dementia.
Additional file 4: Figure S4. Schematic Figure representing the WNT pathway as described in the Biocarta database. In red are labeled the dementia network mediator proteins.

Abbreviations

FTD: Frontotemporal dementia; AD: Alzheimer disease; LBD: Lewy bodies disease; PSP: Progressive supranuclear palsy; CBD: Corticobasal dementia; HD: Huntington’s disease; ALS/SP: Amyotrophic lateral sclerosis-Parkinsonism/dementia complex; PTPN: Protein–protein interaction network; GSK3β: Glycogen synthase kinase beta; AMPK: AMP-activated kinase; TDP-43: TAR DNA-binding protein 43; PP2A: Protein phosphatase 2A.

Competing interests

The authors declare that there is no competing interest in relation to the publication of this article.

Authors’ contributions

LC and TPN conceived and designed the study, collected and analyzed the manuscript.

Acknowledgments

We are grateful to Bianca Baldacci for the graphic design contribution and to Corrado Priami and Mario Lauria for valuable discussions.

Received: 14 January 2014 Accepted: 20 May 2014

Published: 7 June 2014

References

1. Hickey C, Chisholm T, Passmore MJ, O’Brien JD, Johnston J: Differentiating the dementias: revisiting synucleinopathies and tauopathies. Curr Alzheimer Res 2008, 5:552–60.
2. Galpern WR, Lang AE: Interface between tauopathies and synucleinopathies: a tale of two proteins. Ann Neurol 2006, 59:449–458.
3. Loscalzo J, Barabasi A-L: Systems biology and the future of medicine. Wiley Interdiscip Rev Syst Biol Med 2011, 3:619–627.
4. Barabasi A-L, Gulbahce N, Loscalzo J: Network medicine: a network-based approach to human disease. Nat Rev Genet 2011, 12:56–68.
5. Vidal M, E Cubicci, Barabasi A-L: Interactome networks and human disease, Cell 2011, 144:986–998.
6. Ott M, Snell B, Huygen MA, Brunner HG: Predicting disease genes using protein-protein interactions. J Med Genet 2006, 43:691–698.
7. Kann MG: Protein interactions and disease: computational approaches to uncover the etiology of diseases. Brief Bioinform 2007, 8:333–346.
8. Schuster-Böckler B, Bateman A: Protein interactions in human genetic diseases. Genome Biol 2008, 9:R9.
9. Navlakha S, Kingsford C: The power of protein interaction networks for associating genes with diseases. Bioinformatics 2010, 26:1057–1063.
10. Nguyen T-P, Ho T-B: Detecting disease genes based on semi-supervised learning and protein-protein interaction networks, Artif Intell Med 2012, 54:63–71.
11. Jordán F, Nguyen T-P, Liu W-C: Studying protein-protein interaction networks: a systems view on diseases. Brief Funct Genomics 2012, 11:497–504.
12. Caberlotto L, Lalita M, Nguyen T-P, Priami C: The central role of AMP-kinase and energy homeostasis impairment in Alzheimer’s disease: a multifactor network analysis. PLoS One 2013, 8(11):e89919.
13. Thanh-Phuong N, Laura C, Morine CP-M: Network analysis of neurodegenerative disease highlights a role of toll-like receptor signaling. Biomed Res Int 2014, 2014:685050.
14. Caberlotto L, Lalita M, Nguyen T-P, Scotti M: The central role of AMP-kinase and energy homeostasis impairment in Alzheimer’s disease: a multifactor network analysis. PLoS One 2013, 8(11):e89919.
15. Chen X, Burgoine RD: Identification of common genetic modifiers of neurodegenerative diseases from an integrative analysis of diverse genetic screens in model organisms. BMC Genomics 2012, 13:71.
16. Limviphuvadh V, Tanaka S, Goto S, Ueda K, Kanehisa M: The commonality of protein interaction networks determined in neurodegenerative disorders (NDDs). Bioinformatics 2007, 23:2129–2138.
17. Vasalak SV, Padhi AK, Jayaram B, Gomes J: NeuroDNet - an open source platform for constructing and analyzing neurodegenerative disease networks. BMC Neurosci 2013, 14:3.
18. Gad SC: Pharmaceutical Sciences Encyclopedia. Hoboken, NJ, USA: John Wiley & Sons, Inc; 2010.
19. Yu H, Chen J, Xu X, Li Y, Zhao H, Fang Y, Li X, Zhou W, Wang W, Wang Y: A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 2012, 7:e37608.
20. Emgi D, Iliiev A, Pustovoitova O, Lancashire L, Bureeva S, Nikolisky Y, Bessarabova M: Drug target prediction and repositioning using an integrated network-based approach. PLoS One 2013, 8:e806818.
21. Hamosh A, Scott AF, Amberg ter JS, Rocchi CA, McKusick VA: Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders. Nucleic Acids Res 2005, 33(Database issue):DS14–DS17.
22. Baxevanis AD: Searching Online Mendelian Inheritance in Man (OMIM) for information for genetic loci involved in human disease. Curr Protoc Hum Genet 2003, Chapter 9Unit9.13.
23. Brown KR, Jurisica I: Online predicted human interaction database. Bioinformatics 2005, 21:2076–2082.
24. Zoten S, Mestre J, OReilly DP, Przytycka TM: Why do hubs in the yeast protein interaction network tend to be essential: reexaming the connection between the network topology and essentiality. PLoS Comput Biol 2008, 4:e1000490.
25. Zhang S, Jin G, Zhang Y-S, Shen L: Discovering functions and revealing mechanisms at molecular level from biological networks. Proteomics 2007, 7:2856–2869.
26. Yook S-H, Oltvai ZN, Barabasi A-L: Functional and topological characterization of protein interaction networks. Proteomics 2004, 4:928–942.
27. Eden E, Navon R, Steinfeld I, Lipsin D, Yaknih Z: GoRilla: a tool for discovery and visualization of enriched GO terms in ranked gene lists. BMC Bioinformatics 2009, 10:48.
28. Supek F, Bolinak M, Skunca N, Smuc T: REVIGO summarizes and visualizes long lists of gene ontology terms. PLoS One 2011, 6:e21800.
29. Behrends C, Sowa ME, Gijy SP, Harper JW: Network organization of the human autophagy system. Nature 2010, 466:68–76.
30. Salminen A, Kaarniranta K, Haapasalo A, Soininen H, Hiltunen M: AMP-activated protein kinase: a potential player in Alzheimer’s disease. J Neurochem 2011, 118:460–474.
31. Cai Z, Yan L-J, Li K, Quzh SH, Zhao B: Roles of AMP-activated protein kinase in Alzheimer’s disease. NeuroMolecular Med 2012, 14:1–14.
32. Vingtdeux V, Davies P, Dickson DW, Marambaud P: Autophagy and neurodegeneration. Autophagy 2013, 9:2315–317.
33. Iqbal K, Grundke-Iqbal I: Metabolic/signal transduction hypothesis of Alzheimer’s disease and other tauopathies. Acta Neuropathol 2011, 123:397–407.
34. Iqbal K, Grundke-Iqbal I: Metabolic/signal transduction hypothesis of Alzheimer’s disease and other tauopathies. Acta Neuropathol 2011, 123:397–407.
35. Mitakhina N, Levine B, Cuervo AM: Klondyke DJ: Autophagy fights disease through cellular self-digestion. Nature 2008, 451:1068–1075.
36. Klondyke DJ, Emry SD: Autophagy as a regulated pathway of cellular degradation. Science 2000, 290:1717–1721.
37. Levine B, Yuan J: Autophagy in cell death: an innocent convict? J Clin Invest 2005, 115:2679–2688.
38. Roach PJ: AMPK: - > ULKI - > autophagy. Mol Cell Biol 2011, 31:3082–3084.
39. Komatsu M, Kominami E, Tanaka K: Autophagy and neurodegeneration. Autophagy 2006, 2:315–317.
40. Martín A, Joseph JA, Cuervo AM: Stimulatory effect of vitamin C on autophagy in glial cells. J Neurochem 2002, 82:538–549.
41. Qin A-P, Liu C-F, Qin Y-Y, Hong L-Z, Xu M, Yang L, Liu J, Qin Z-H, Zhang H-L: Autophagy was activated in injured astrocytes and mildly decreased cell survival following glucose and oxygen deprivation and focal cerebral ischemia. Autophagy 2010, 6:308–308.
42. Krüg CL, Ubbi K, Wyss-Coray T, Wyss-Coray T, Masliah E: Autophagy in dementia. Brain Pathol 2012, 22:99–109.
43. Salminen A, Kaarniranta K, Kauppinen A, Oja P, Kaapanala A, Soininen H, Hiltunen M: Impaired autophagy and APP processing in Alzheimer’s disease: The potential role of Berlin 1 interactome. Prog Neurobiol 2013, 106:109–23.
43. Pattingre S, Tassa A, Xu Q, Gunati R, Liang XH, Mizushima N, Packer M, Schneider MD, Levine B: Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell 2005, 122:927–939.

44. Kanazawa T, Taneike I, Akaishi R, Yoshizawa F, Furuya N, Fujimura S, Kanazawa T, Taneike I, Akaishi R, Yoshizawa F, Furuya N, Fujimura S, Pattingre S, Tassa A, Qu X, Garuti R, Liang XH, Mizushima N, Packer M, Canerlotto and Nguyen http://www.biomedcentral.com/1752-0509/8/65

45. Furuya T, Kim M, Lipinski M, Li J, Du L, T, Shen Y, Rameh L, Yankner B, Tsai L-H, Yuan J. Negative regulation of Vps34 by Cdk mediated phosphorylation. Mol Cell 2010, 38:500–511.

46. Funderburk SF, Wang QJ, Yue Z. The Beclin 1–VPS34 complex–at the crossroads of autophagy and beyond. Trends Cell Biol 2010, 20:355–362.

47. He C, Levine B. The Beclin 1 interactome. Curr Opin Cell Biol 2010, 22:140–149.

48. Cataldo AM, Peterhoff CM, Schmidt SD, Terbo NB, Duff K, Beard M, Mathews PM, Nixon RA: Presenilin mutations in familial Alzheimer disease and transgenic mouse models accelerate neuronal lysosomal pathology. J Neuropathol Exp Neurol 2004, 63:211–830.

49. Cataldo AM, Barnett J, Mann DM, Nixon RA: Colocalization of lysosomal hydrolase and beta-amyloid in diffuse plaques of the cerebellum and striatum in Alzheimer’s disease and Down’s syndrome. J Neuropathol Exp Neurol 1996, 55:704–715.

50. Cataldo AM, Hamilton DJ, Nixon RA: Lysosomal abnormalities in degenerating neurons link neuronal compromise to senile plaque development in Alzheimer disease. Brain Res 1994, 640:68–80.

51. Cataldo AM, Hamilton DJ, Barnett JL, Paskevich PA, Nixon RA: Properties of the endosomal-lysosomal system in the human central nervous system: disturbances mark most neurons in populations at risk to degenerate in Alzheimer’s disease. J Neurosci 1996, 16:186–199.

52. Mufson EJ, Counts SE, Ginsberg SD: Gene expression profiles of cholinergic nuclear basalis neurons in Alzheimer’s disease. Neurochem Res 2002, 27:1035–1048.

53. Grinsberg SD, Allred MD, Counts SE, Cataldo AM, Neve RL, Jiang Y, Wu J, Chao MV, Mufson EJ, Nixon RA, Che S: Microarray analysis of hippocampal CA1 neurons implicates early endosomal dysfunction during Alzheimer’s disease progression. Biol Psychiatry 2010, 68:885–893.

54. Nixon RA, Cataldo AM: Lysosomal system pathways: genes to neurodegeneration in Alzheimer’s disease. J Alzheimers Dis 2006, 9:3 Suppl:277–289.

55. Lipinski MM: Towards the global understanding of the autophagy regulatory network. Autophagy 2010, 6:1218–1220.

56. Barton AJ, Crook BW, Karran EH, Brown F, Dewar D, Mann DM, Pearson RC, Graham DI, Hardy J, Hutton M, Duff K, Goate AM, Clark RF, Roberts GW: Alteration in brain presenilin 1 mRNA expression in early onset familial Alzheimer’s disease. Neurodegeneration 1996, 5:213–218.

57. Borchelt DR, Rattovitski T, Van Lare J, Lee MK, Gonzalez V, Jenkins NA, Copeland NG, Price DL, Sidos SA: Accelerated amyloid deposition in the brains of transgenic mice coexpressing mutant presenilin 1 and amyloid precursor proteins. Neuron 1997, 19:939–945.

58. Gómez-Isla T, Growdon WB, McNamara MJ, Nochlin D, Bird TD, Arango JC, Martinez A, Gil C, Perez D: Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer’s disease treatment. Int J Alzheimers Dis 2011, 2011:28052.

59. Patel DJ, Crook BW, Parsek A-A: Mitochondrial dysfunction and amyloid pathology in an Alzheimer’s disease mouse model. J Alzheimers Dis 2004, 7:337–345.

60. Lee J-H, Yu WH, Kumar A, Lee S, Mohan PS, Peterhoff CM, Wolfe DM, Murphy MP, Chen K-C, Blalock EM, Landfield PW, Porter NM, Thibault O, Milhout O: Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer’s disease. J Alzheimers Dis 2012, 32:943–961.

Cite this article as: Caberlotto and Nguyen: A systems biology investigation of neurodegenerative dementia reveals a pivotal role of autophagy, BMC Systems Biology 2014 8:65.

Submit your next manuscript to BioMed Central and take full advantage of:

• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit